230 related articles for article (PubMed ID: 33326461)
21. Reduced Serum Cholesterol and Triglyceride Levels in a Choline-Deficient L-Amino Acid-Defined High-Fat Diet (CDAHFD)-Induced Mouse Model of Non-alcoholic Steatohepatitis (NASH).
Yasuda D; Torii H; Shimizu R; Hiraoka Y; Kume N
Biol Pharm Bull; 2020; 43(4):616-618. PubMed ID: 32238704
[TBL] [Abstract][Full Text] [Related]
22. PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat.
Okishio S; Yamaguchi K; Ishiba H; Tochiki N; Yano K; Takahashi A; Kataoka S; Okuda K; Seko Y; Liu Y; Fujii H; Takahashi D; Ito Y; Kamon J; Umemura A; Moriguchi M; Yasui K; Okanoue T; Itoh Y
Sci Rep; 2020 Nov; 10(1):19578. PubMed ID: 33177546
[TBL] [Abstract][Full Text] [Related]
23. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.
Baandrup Kristiansen MN; Veidal SS; Christoffersen C; Feigh M; Vrang N; Roth JD; Erickson M; Adorini L; Jelsing J
BMC Gastroenterol; 2019 Dec; 19(1):228. PubMed ID: 31883514
[TBL] [Abstract][Full Text] [Related]
24. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
Abd El-Haleim EA; Bahgat AK; Saleh S
Eur J Pharmacol; 2016 Feb; 773():59-70. PubMed ID: 26825546
[TBL] [Abstract][Full Text] [Related]
25. Deletion of TRPC3 or TRPC6 Fails to Attenuate the Formation of Inflammation and Fibrosis in Non-alcoholic Steatohepatitis.
Nishiyama K; Toyama C; Kato Y; Tanaka T; Nishimura A; Nagata R; Mori Y; Nishida M
Biol Pharm Bull; 2021; 44(3):431-436. PubMed ID: 33642551
[TBL] [Abstract][Full Text] [Related]
26. Effects of Caffeine and Chlorogenic Acid on Nonalcoholic Steatohepatitis in Mice Induced by Choline-Deficient, L-Amino Acid-Defined, High-Fat Diet.
Dungubat E; Watabe S; Togashi-Kumagai A; Watanabe M; Kobayashi Y; Harada N; Yamaji R; Fukusato T; Lodon G; Sevjid B; Takahashi Y
Nutrients; 2020 Dec; 12(12):. PubMed ID: 33353230
[TBL] [Abstract][Full Text] [Related]
27. Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH.
Boeckmans J; Buyl K; Natale A; Vandenbempt V; Branson S; De Boe V; Rogiers V; De Kock J; Rodrigues RM; Vanhaecke T
Pharmacol Res; 2019 Jun; 144():377-389. PubMed ID: 31028903
[TBL] [Abstract][Full Text] [Related]
28. Nonobese mice with nonalcoholic steatohepatitis fed on a choline-deficient, l-amino acid-defined, high-fat diet exhibit alterations in signaling pathways.
Suzuki-Kemuriyama N; Abe A; Nakane S; Uno K; Ogawa S; Watanabe A; Sano R; Yuki M; Miyajima K; Nakae D
FEBS Open Bio; 2021 Nov; 11(11):2950-2965. PubMed ID: 34390210
[TBL] [Abstract][Full Text] [Related]
29. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
[TBL] [Abstract][Full Text] [Related]
30. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
Akbari R; Behdarvand T; Afarin R; Yaghooti H; Jalali MT; Mohammadtaghvaei N
BMC Pharmacol Toxicol; 2021 Oct; 22(1):53. PubMed ID: 34593018
[TBL] [Abstract][Full Text] [Related]
31. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
32. Elevation of liver endoplasmic reticulum stress in a modified choline-deficient l-amino acid-defined diet-fed non-alcoholic steatohepatitis mouse model.
Muraki Y; Makita Y; Yamasaki M; Amano Y; Matsuo T
Biochem Biophys Res Commun; 2017 May; 486(3):632-638. PubMed ID: 28322783
[TBL] [Abstract][Full Text] [Related]
33. A CDAHFD-induced mouse model mimicking human NASH in the metabolism of hepatic phosphatidylcholines and acyl carnitines.
Yang J; Dai M; Wang Y; Yan Z; Mao S; Liu A; Lu C
Food Funct; 2024 Mar; 15(6):2982-2995. PubMed ID: 38411344
[TBL] [Abstract][Full Text] [Related]
34. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Boeckmans J; Natale A; Rombaut M; Buyl K; Rogiers V; De Kock J; Vanhaecke T; M Rodrigues R
Cells; 2019 Dec; 9(1):. PubMed ID: 31877771
[TBL] [Abstract][Full Text] [Related]
35. Concomitant PPARα and FXR Activation as a Putative Mechanism of NASH Improvement after Gastric Bypass Surgery: a GEO Datasets Analysis.
Mazzini GS; Khoraki J; Dozmorov M; Browning MG; Wijesinghe D; Wolfe L; Gurski RR; Campos GM
J Gastrointest Surg; 2019 Jan; 23(1):51-57. PubMed ID: 30206765
[TBL] [Abstract][Full Text] [Related]
36. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
Kumar DP; Caffrey R; Marioneaux J; Santhekadur PK; Bhat M; Alonso C; Koduru SV; Philip B; Jain MR; Giri SR; Bedossa P; Sanyal AJ
Sci Rep; 2020 Jun; 10(1):9330. PubMed ID: 32518275
[TBL] [Abstract][Full Text] [Related]
37. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
[TBL] [Abstract][Full Text] [Related]
38. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis.
Francque S; Verrijken A; Caron S; Prawitt J; Paumelle R; Derudas B; Lefebvre P; Taskinen MR; Van Hul W; Mertens I; Hubens G; Van Marck E; Michielsen P; Van Gaal L; Staels B
J Hepatol; 2015 Jul; 63(1):164-73. PubMed ID: 25703085
[TBL] [Abstract][Full Text] [Related]
39. Alpha-syntrophin null mice are protected from non-alcoholic steatohepatitis in the methionine-choline-deficient diet model but not the atherogenic diet model.
Rein-Fischboeck L; Haberl EM; Pohl R; Schmid V; Feder S; Krautbauer S; Liebisch G; Buechler C
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 May; 1863(5):526-537. PubMed ID: 29474931
[TBL] [Abstract][Full Text] [Related]
40. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.
Jain MR; Giri SR; Bhoi B; Trivedi C; Rath A; Rathod R; Ranvir R; Kadam S; Patel H; Swain P; Roy SS; Das N; Karmakar E; Wahli W; Patel PR
Liver Int; 2018 Jun; 38(6):1084-1094. PubMed ID: 29164820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
